カテゴリ： GlobalData, アメリカ, 企業調査

CymaBay Therapeutics Inc (CBAY)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：CymaBay Therapeutics Inc (CBAY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9775
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：56
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
CymaBay Therapeutics Inc (CymaBay), formerly Metabolex Inc is a clinical-stage biopharmaceutical company that develops therapeutics to treat diabetes, orphan diseases and related metabolic disorders. The company’s pipeline products comprise Arhalofenate, an oral small molecule intended for the treatment of Gout flares. It also develops MBX-2982 and MBX-8025 for patients with type 2 diabetes, orphan indications and for various diseases affecting liver functions. The company has collaboration with various pharmaceutical companies and others to develop its product candidates. CymaBay is headquartered in Newark, California, the US.

CymaBay Therapeutics Inc (CBAY) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
CymaBay Therapeutics Raises USD26.8 Million in Venture Financing 11
Partnerships 12
HistoIndex and CymaBay Therapeutics Enter into Partnership 12
Equity Offering 13
CymaBay Therapeutics Raises USD114 Million in Public Offering of Shares 13
CymaBay Therapeutics Raises USD97 Million in Public Offering of Shares 15
CymaBay Therapeutics Raises USD10 Million in Public Offering of Shares 17
CymaBay Therapeutics Raises USD0.3 Million in Private Placement of Securities 18
CymaBay Therapeutics Raises USD23 Million in Public Offering of Shares 19
CymaBay Therapeutics Raises USD25.3 Million in Public Offering of Shares 21
CymaBay Therapeutics Completes Third Tranche Of Private Placement Of Shares For US$33.2 Million 23
CymaBay Therapeutics Inc – Key Competitors 24
CymaBay Therapeutics Inc – Key Employees 25
CymaBay Therapeutics Inc – Locations And Subsidiaries 26
Head Office 26
Recent Developments 27
Financial Announcements 27
Nov 06, 2018: CymaBay reports third quarter 2018 financial results and provides corporate update 27
Nov 06, 2018: Cymabay reports third quarter 2018 financial results and provides corporate update 29
Aug 09, 2018: Cymabay reports second quarter 2018 financial results and provides corporate update 31
May 08, 2018: CymaBay Reports First Quarter 2018 Financial Results and Provides Corporate Update 33
Mar 15, 2018: CymaBay Announces Fourth Quarter and Fiscal 2017 Financial Results 34
Nov 08, 2017: CymaBay Reports Third Quarter 2017 Financial Results and Corporate Updates 36
Aug 10, 2017: CymaBay Reports Second Quarter 2017 Financial Results and Provides Corporate Update 37
May 11, 2017: CymaBay Reports First Quarter 2017 Financial Results and Provides Corporate Update 39
Mar 23, 2017: CymaBay Reports Fourth Quarter and Year End 2016 Financial Results 40
Corporate Communications 41
Mar 29, 2017: CymaBay Announces the Retirement of President and Chief Executive Officer, Harold Van Wart, Ph.D. 41
Product News 42
10/31/2017: CymaBay Announces the Appointment of Sujal Shah as President and Chief Executive Officer 42
06/19/2018: CymaBay Therapeutics to Host Analyst and Investor Day on June 26, 2018 43
01/08/2018: CymaBay Therapeutics: Enrollment Begins in Long-Term Extension Study of Seladelpar in Patients with Primary Biliary Cholangitis 44
01/08/2018: CymaBay Therapeutics Receives $5 Million Milestone Payment for Arhalofenate from Kowa Pharmaceuticals America 45
Product Approvals 46
Sep 11, 2017: CymaBay Therapeutics Granted EMA Orphan Drug Designation for Seladelpar for the Treatment of Primary Biliary Cholangitis 46
Clinical Trials 47
May 08, 2018: CymaBay Therapeutics Announces the Initiation of a Phase 2b Study of Seladelpar in Patients with Non-Alcoholic Steatohepatitis 47
Apr 11, 2018: CymaBay Announces Positive New 12-Week and 26-Week Results from its Ongoing Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis at The International Liver Congress 2018 48
Oct 23, 2017: CymaBay to Host Post-AASLD Key Opinion Leader Meeting on Novel Treatments for Primary Biliary Cholangitis 50
Oct 09, 2017: CymaBay Announces Oral Late-Breaking Presentation of Interim Results from an Ongoing Phase 2 Study of Patients with Primary Biliary Cholangitis at the AASLD 2017 Liver Meeting 51
Aug 15, 2017: CymaBay Therapeutics Announces the Publication of the Seladelpar Proof-of-Concept Study for Primary Biliary Cholangitis in Lancet Gastroenterology and Hepatology 52
Jul 17, 2017: CymaBay Announces Positive Interim Results from Its Ongoing Low-Dose Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis 53
Apr 13, 2017: CymaBay to Present Data from its Phase 2 Proof-of-Concept Study of Seladelpar in Patients With Primary Biliary Cholangitis at the EASL Liver Meeting 2017 54
Jan 05, 2017: CymaBay Therapeutics Announces Successful Completion of Scientific Advice Discussions with the European Medicines Agency for Arhalofenate 55
Appendix 56
Methodology 56
About GlobalData 56
Contact Us 56
Disclaimer 56

List of Tables
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CymaBay Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
CymaBay Therapeutics Raises USD26.8 Million in Venture Financing 11
HistoIndex and CymaBay Therapeutics Enter into Partnership 12
CymaBay Therapeutics Raises USD114 Million in Public Offering of Shares 13
CymaBay Therapeutics Raises USD97 Million in Public Offering of Shares 15
CymaBay Therapeutics Raises USD10 Million in Public Offering of Shares 17
CymaBay Therapeutics Raises USD0.3 Million in Private Placement of Securities 18
CymaBay Therapeutics Raises USD23 Million in Public Offering of Shares 19
CymaBay Therapeutics Raises USD25.3 Million in Public Offering of Shares 21
CymaBay Therapeutics Completes Third Tranche Of Private Placement Of Shares For US$33.2 Million 23
CymaBay Therapeutics Inc, Key Competitors 24
CymaBay Therapeutics Inc, Key Employees 25

List of Figures
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CymaBay Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[CymaBay Therapeutics Inc (CBAY)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Mitsui & Co Ltd (8031)：石油・ガス：M&Aディール及び事業提携情報
    Summary Mitsui & Co Ltd (Mitsui) is a business conglomerate. The company sells, distributes, purchases, markets and supplies wide variety of products in business areas including iron and steel; non-ferrous metals; machinery; electronics; chemicals; energy-related commodities; foods & retail, lifesty …
  • Trustpower Limited (TPW)-エネルギー分野：企業M&A・提携分析
    Summary TrustPower Limited (Trustpower) is an energy utility that retails electricity, gas and telecommunication services. The company produces electricity from wind, hydro, and diesel sources. It owns and operates various power projects across New Zealand and Australia. Trustpower also leases elect …
  • Evotec AG (EVT)：医療機器：M&Aディール及び事業提携情報
    Summary Evotec AG (Evotec) is a drug discovery alliance and development partnership company. It identifies and develops small molecule drugs across various therapeutic areas such as, cancer, neurological and nephrological conditions, cardiovascular, inflammation, pain, metabolic and respiratory dise …
  • Tampa Electric Co：電力：M&Aディール及び事業提携情報
    Summary Tampa Electric Company (TEC), a subsidiary of Emera Inc., is an energy utility. It conducts the generation, purchase, transmission, distribution and sale of electricity and the distribution, purchase and sale of natural gas in Florida. The service area for electric operations covers West Cen …
  • Analytik Jena AG：企業の戦略的SWOT分析
    Analytik Jena AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Cosmo Pharmaceuticals NV (COPN)：医療機器：M&Aディール及び事業提携情報
    Summary Cosmo Pharmaceuticals NV (Cosmo) is a pharmaceutical company that develops drugs for the treatment of gastro-intestinal diseases. The company develops its pharmaceutical products based on its multi matrix technology. Its proprietary clinical development pipeline intended for the treatment of …
  • Square Inc：企業のM&A・事業提携・投資動向
    Square Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Square Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • Proxy Biomedical Ltd-医療機器分野：企業M&A・提携分析
    Summary Proxy Biomedical Ltd (PBL) is a medical device company that research, develops and manufactures biomaterials for medical implant products. The company’s products include composite mesh, flat sheet 2D and 3D mesh, hernia plugs, resorbable synthetic mesh, resorbable surgical mesh, specialty su …
  • Alexion Pharmaceuticals Inc (ALXN)：企業の財務・戦略的SWOT分析
    Alexion Pharmaceuticals Inc (ALXN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Tennessee Valley Authority：企業の発電所・SWOT分析2018
    Tennessee Valley Authority - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key em …
  • KeyCorp (KEY)：電力：M&Aディール及び事業提携情報
    Summary KeyCorp (KeyCorp) is a bank holding company that offers a range of retail and commercial banking, consumer finance, commercial mortgage and special servicing, commercial leasing, investment management, and investment banking products and services through its principle subsidiary, KeyBank Nat …
  • Blue Label Telecoms Ltd (BLU)：企業の財務・戦略的SWOT分析
    Blue Label Telecoms Ltd (BLU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Nintendo Co Ltd (7974)：企業の財務・戦略的SWOT分析
    Nintendo Co Ltd (7974) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Electricity Supply Board
    Electricity Supply Board - Strategy, SWOT and Corporate Finance Report Summary Electricity Supply Board - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • SMBC Consumer Finance Co Ltd：企業の戦略・SWOT・財務情報
    SMBC Consumer Finance Co Ltd - Strategy, SWOT and Corporate Finance Report Summary SMBC Consumer Finance Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Cardia Inc：医療機器：M&Aディール及び事業提携情報
    Summary Cardia Inc (Cardia) is a medical device company that designs, manufactures and markets transcatheter septal occluders for cardiac defect patients. The company offers products such as ultrasept ASD occluder, ultrasept LAA occluder, ultrasept PFO occluder, fontan occluder, ultrasept cribriform …
  • Marico Limited (MARICO)：企業の財務・戦略的SWOT分析
    Marico Limited (MARICO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Intercept Pharmaceuticals Inc (ICPT)：企業の財務・戦略的SWOT分析
    Intercept Pharmaceuticals Inc (ICPT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Ipsos SA (IPS)：企業の財務・戦略的SWOT分析
    Ipsos SA (IPS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Super Dragon Technology Co., Ltd. (9955)：企業の財務・戦略的SWOT分析
    Super Dragon Technology Co., Ltd. (9955) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆